Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait

Mycoses

Volumn 51, Issue 4, 2008, Pages 318-323

  Asadzadeh, Mohammad ^a   Al Sweih, Noura A ^a   Ahmad, Suhail ^a   Khan, Zia U ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antifungal agents; Antifungal susceptibility; Candida parapsilosis; Caspofungin; Etest

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; EPSILOMETER TEST; FUNGUS ISOLATION; INCUBATION TIME; KUWAIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; KUWAIT; MICROBIAL SENSITIVITY TESTS; TEMPERATURE; TIME FACTORS;

CANDIDA PARAPSILOSIS;

EID: 44849120974     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01492.x     Document Type: Article

References (37)

1. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006 44 : 1681 5.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 : 133 63.
3. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003 37 : 634 43.
4. Weems JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992 14 : 756 66.
5. Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005 43 : 2729 35.
6. Levin AS, Costa SF, Mussi NS et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998 30 : 243 9.
7. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immunol 2002 70 : 878 88.
8. Bonassoli LA, Bertoli M, Svidzinski TI. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect 2005 59 : 159 62.
9. Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R. Epidemiology of candidemia - a nationwide survey in Israel. Infection 2000 28 : 26 29.
10. Mokaddas EM, Ramadan SA, Abo el Maaty SH, Sanyal SC. Candidemia in pediatric surgery patients. J Chemother 2000 12 : 332 8.
11. Bukharie HA. Nosocomial candidemia in a tertiary care hospital in Saudi Arabia. Mycopathologia 2002 153 : 195 8.
12. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007 56 : 255 9.
13. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2000 2 : 73 85.
14. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005 49 : 767 9.
15. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006 34 : 345 8.
16. Ahmad S, Khan Z, Mustafa AS, Khan ZU. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J Clin Microbiol 2002 40 : 2483 9.
17. Clinical and Laboratory Standards Institute (formerly NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard, M27-A2. Wayne, PA, USA : 2002.
18. Clinical and Laboratory Standards Institute. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints Appendix C) (M27-S2). Wayne, PA, USA : 2006.
19. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003 47 : 3149 54.
20. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp to caspofungin: four years of global surveillance. J Clin Microbiol 2006 44 : 760 3.
21. Colombo AL, Nucci M, Salomao R et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999 34 : 281 6.
22. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006 6 : 21 26.
23. Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005 43 : 5848 59.
24. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004 48 : 201 5.
25. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005 43 : 3807 10.
26. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006 50 : 917 21.
27. Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J Clin Microbiol 2001 39 : 4387 9.
28. Laverdiere M, Restieri C, Habel F. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int J Antimicrob Agents 2002 20 : 468 71.
29. Arikan S, Sancak B, Hascelik G. In vitro activity of vcaspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005 43 : 171 8.
30. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006 50 : 2719 27.
31. Fleck R, Dietz A, Hof H. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J Antimicrob Chemother 2007 59 : 767 71.
32. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global Surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J Clin Microbiol 2006 44 : 3533 8.
33. Alexander BD, Byrne TC, Smith KL et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007 45 : 698 706.
34. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000 46 : 485 7.
35. Mora-Duarte J, Betts R, Rotstein C et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
36. Odds FC, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004 42 : 3475 82.
37. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical Effect of echinocandins across Candida Species in vitro: evidence for echinocandin- specific and Candida species-related differences. Antimicrob Agents Chemother 2007 51 : 2257 9.